Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies
08:01am, Thursday, 12'th Jun 2025
AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a leader in AI-powered drug discovery and biotherapeutics, today announced compelling in vitro results demonst
Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule
09:05am, Wednesday, 11'th Jun 2025
Oral DehydraTECH-liraglutide showed a pronounced reduction in adverse events (“AEs”) as compared to injected liraglutide (Saxenda(R)) Lexaria has now demonstrated, in distinct human clinical stu
Global Partners LP Announces Pricing of Upsized Private Offering of Senior Notes
02:56pm, Tuesday, 10'th Jun 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global”) today announced that it has priced an upsized private offering of $450 million in aggregate principal amount of 7.125% se
Global Partners LP Announces Cash Tender Offer for Any and All Outstanding 7.00% Senior Notes Due 2027
07:35am, Tuesday, 10'th Jun 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global”) announced today that it has commenced a cash tender offer (the “offer”) to purchase any and all of the outstanding 7.
Global Partners LP Announces Private Offering of Senior Notes
07:34am, Tuesday, 10'th Jun 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global”) today announced that it intends to commence a private offering to eligible purchasers, subject to market and other condit
Omada Health IPO to Price at $19 a Share as GLP-1s Fuel Interest
08:21am, Friday, 06'th Jun 2025
Omada Health is making its public-market debut, propelled by Americans' renewed focus on how weight affects physical health.
Lilly's Jake Van Naarden: Lilly's success with GLP-1's allows us to reinvest in oncology
09:39am, Thursday, 05'th Jun 2025
CNBC's Angelica Peebles sits down with Lilly's Head of Oncology, Jake Van Naarden, to discuss what's next in Lilly's oncology pipeline and what Lilly is changing about its clinical trials to make them
IFF Unveils Game-Changing Outlook on GLP-1 Consumers
11:00am, Wednesday, 04'th Jun 2025
NEW YORK--(BUSINESS WIRE)--IFF (NYSE: IFF), a global leader in food, beverage, and health and wellness, has released a new report highlighting how the rapidly growing GLP-1 consumer market is reshapin
Global Partners Mourns the Loss of Board Chairman Richard Slifka
04:05pm, Tuesday, 27'th May 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) announces with deep sadness the passing of Richard Slifka, Chairman of the Board of Directors of the Partnership's general partner, Glob
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside?
01:41pm, Tuesday, 27'th May 2025
With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.
Novo Nordisk's GLP-1 lead narrows, but long-term thesis still holds
12:14pm, Tuesday, 27'th May 2025
A fresh physician poll has revived debate over the shifting balance of power in the weight-loss drug market. According to Deutsche Bank, the snapshot shows a marginal swing in favour of Eli Lilly and
Should everyone be taking drugs like Ozempic? Drugs in the GLP-1-category show promise for a growing list of health conditions
10:00pm, Sunday, 25'th May 2025
GLP-1 drugs for weight loss and treating diabetes show promise for an ever-expanding list of diseases.
NorthStrive Biosciences Announces Completion of Phase I Strategic Review for EL-22 Targeting Muscle Loss Associated with GLP-1 Weight Loss Drugs and Age-Re
CheqUp and WeightWatchers Announce Strategic Partnership to Support Growing Use of GLP-1 Medications in the UK
02:00am, Thursday, 22'nd May 2025
Partnership Provides CheqUp Members Access to WeightWatchers' Proven GLP-1 Companion Programme to Aid in Achieving Superior and Sustainable Results Partnership Provides CheqUp Members Access to Weight
Pepsi: Forget GLP-1 And Dividend Cuts, These Are The Real Reasons Why It's Crashing
09:00am, Saturday, 17'th May 2025
Pepsi's slump is mainly due to aggressive price hikes and high T-bond yields, not diworsification or health trends. Core profitability and capital efficiency remain strong; dividend sustainability con
